u/ines_castellanos

Phase 2 TRIUMPH looked amazing. Phase 3 trials are harder. Do not anchor on phase 2 readouts.

absolute risk reduction, not relative risk reduction, that is how you decide

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

Is that absolute or relative risk reduction?

SELECT reported a SURMOUNT hazard ratio but the absolute event rate is what changes clinical practice.

week 84 and i am still not at maintenance, do not rush the ladder

Did you test the vial you received or are we going off the vendor COA?

That is net peptide content, not purity. Different number, different meaning.

give the trial name, phase, n, and primary endpoint in the body

Yes, exactly this, and it is the bit that took me 65 weeks to accept.

MHRA supply notices change monthly, follow the actual list

nope, 0.25 counts, it is just not the dose most people stay on

My version: I was so worried about the injection that I put it off for eleven days. The injection is the easiest part. Nobody believes that until they do it.

Cosigning. The slow route gets the outcome, the fast route gets you the side effects.

private prescription routes vary by region

number-needed-to-treat is the house dialect

No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.

No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.

Yeah, the NHS waitlist is genuinely two years in most places.

the quiet is real. the food noise just stops.

Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.